profit from every $100 of sales.
$0$100
LB Pharmaceuticals
$44.71-0.51% today
+199.9% in 1 year
1-year low $14.911-year high $49.48
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What LB Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$25.2 million of profit last year.
SalesProfit
LB Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| LB Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads LB Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -3 | -11 | -65 | -30 | |
| -12 | -1 | -65 | -30 | |
| -14 | -6 | -63 | -25 | |
| -4.05 | -1.77 | -17.82 | -3.13 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21 | 46 | 34 | 313 |
| Cash | 21 | 15 | 23 | 250 |
| Total debt | 24 | 0 | 4 | 4 |
| Total liabilities | 50 | 80 | 128 | 12 |
| -29 | -34 | -95 | 301 | |
| 22 | 22 | 22 | 8 | |
| – | – | – | -7.9% | |
| 49.8% | 18.2% | 66.7% | -8.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | -12 | -53 | -35 | |
| – | 0 | 1 | 0 | |
| -3 | -12 | -54 | -35 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 3 | 4 |
Valuation
- –
- –
- –
- 2.1×
- –
- –
- –
- -2.4%
- -1.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -12.2%
- 96.8%
- -17.7%
- -10.0%
- -12.2%
- –
Growth
- –
- –
- +34.5%
- –
- +92.6%
Financial health
- 6.9×
- 0.01
- 0.9%
- 226.9×
- 35.68
- 35.68
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 945
Bottom 21%of 870
Bottom 29%of 986
What analysts expect
- Average price target
- $38.00
- Range
- $31.00 – $45.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.67 | -0.75 | +10.7% |
| Mar 26, 2026 | -0.45 | -0.45 | +0.0% |
| Nov 6, 2025 | -0.61 | -0.57 | −7.0% |
News
Eupraxia Pharmaceuticals reports Q3 resultsSeeking Alpha · Nov 11, 2026Ionis Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 6, 2026ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha · Nov 5, 2026Vertex Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 1, 2026Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineYahoo Finance · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
54No pass
Philip Fisher
40No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
43No pass
Terry Smith
47No pass
Questions about LB Pharmaceuticals
Is LB Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the LB Pharmaceuticals AI analysis
What does LB Pharmaceuticals do?
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride. It is in Biotechnology.
Does LB Pharmaceuticals pay a dividend?
No. LB Pharmaceuticals does not pay a dividend at the moment.
Is LB Pharmaceuticals stock halal?
Yes. LB Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has LB Pharmaceuticals stock done over the past year?
Up 199.9% over the past twelve months, to $44.71. It traded between $14.91 and $49.48 and is 9.6% below its high.
Who are LB Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with LB Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.